Albiglutide
| Use attributes for filter ! | |
| Other names | GSK-716155 |
|---|---|
| Elimination half-life | 5 (4–7) days |
| License data | EMA |
| US | |
| FDA | |
| ATC code | A10BJ04 (WHO) |
| Protein binding | Probably none |
| Music groups | Dulaglutide |
| Liraglutide | |
| Exenatide | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2963978 |
About Albiglutide
Albiglutide is a glucagon-like peptide-1 agonist drug marketed by GlaxoSmithKline for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death. GSK has announced that it intends to withdraw the drug from the worldwide market by July 2018 for economic reasons.